Print page Print page
Switch language
Bispebjerg Hospital - a part of Copenhagen University Hospital

The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Desloratadine Use During Pregnancy and Risk of Adverse Fetal Outcomes: A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

    Research output: Contribution to journalReviewpeer-review

  4. Development of the International Severe Asthma Registry (ISAR): a modified Delphi study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Reply to Crépeaux et al and Blasco

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

BACKGROUND: With the introduction of different targeted therapies for type 2 (T2)-high asthma, there is an urgent need for markers to guide the choice of treatment. T2-high asthma includes different clinical phenotypes of asthma, but the prevalence and impact of activation of different T2 inflammatory pathways is unknown.

OBJECTIVE: To describe the level of coexpression of clinically available T2 inflammatory markers in patients with severe asthma, and the relationship with clinical characteristics and comorbidities.

METHODS: Patients with severe asthma according to European Respiratory Society/American Thoracic Society guidelines were examined prospectively including sputum induction and grouped according to T2 biomarkers: blood eosinophilia (≥0.3 × 109/L), total IgE (≥150 U/mL), and fractional exhaled nitric oxide (≥25 parts per billion).

RESULTS: We found 116 (70%) of the 166 patients to have at least 1 T2 biomarker elevated: 39% had 2 or more elevated biomarkers, whereas 31% had only 1 biomarker elevated. Concomitant airway and systemic eosinophilia was present in 28% of all patients, corresponding to half (53%) of the patients with either. Expression patterns of the T2 biomarkers were associated with differences in allergic sensitization and the coexistence of nasal polyposis.

CONCLUSIONS: Most patients with severe asthma showed at least 1 T2 inflammatory trait. Coexpression of T2 biomarkers was highly heterogeneous, and different expression patterns were associated with distinct clinical characteristics.

Original languageEnglish
JournalThe journal of allergy and clinical immunology. In practice
Issue number3
Pages (from-to)1267-1275
Number of pages9
Publication statusPublished - Mar 2021

    Research areas

  • Biologics, Biomarkers, Heterogeneity, Phenotypes, Severe asthma, T2 inflammation

ID: 61434060